Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT ID: NCT01875653
Last Updated: 2019-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
4 participants
INTERVENTIONAL
2014-10-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research study is evaluating if a patient-specific experimental therapy for metastatic melanoma will lengthen survival with minimal harmful effects. It is called an experimental therapy (or "study therapy") because it is not yet approved by the U.S. Food and Drug Administration (FDA). This research study will use the patient's own tumor cells,the patient's own dendritic cells (a type of immune cell), and a granulocyte-macrophage colony stimulating factor (GM-CSF, a type of growth factor). GM-CSF is a natural growth factor that stimulates growth of white blood cells in the body. Since 1991, GM-CSF has been used as a standard treatment to help increase the number of white blood cells after chemotherapy.
The patient's dendritic cells are grown in a test-tube with the patient's tumor cells and the growth factor. The resulting solution is called the study therapy. The intent of the study therapy is to make the dendritic cells more effective at fighting the tumor when they are injected back into the patient.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dendritic Cell Vaccination in Patients With Advanced Melanoma
NCT03092453
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
NCT00672542
Dendritic Cell Based Therapy of Malignant Melanoma
NCT00197912
Melanoma Patients Immunized with Natural DenDritic Cells
NCT02993315
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
NCT00683670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Autologous PBMCs in GM-CSF (MC)
DOSE/ROUTE/REGIMEN:
1. Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.
2. Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.
3. Mode of Administration: Subcutaneous (SC) injections.
Autologous PBMCs in GM-CSF (MC)
Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
DOSE/ROUTE/REGIMEN:
1. Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.
2. Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.
3. Mode of Administration: Subcutaneous (SC) injections.
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)
Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Autologous PBMCs in GM-CSF (MC)
Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Histologic diagnosis of invasive melanoma.
2. Measurable metastatic melanoma with at least one lesion amenable to -resection Stage III: recurrent regional disease, including regional disease with no known primary.
Stage IV: distant metastatic melanoma.
3. Age 18 years and older.
4. Sign the "Tissue Consent", the pre-Clinical Informed Consent for Melanoma Tissue Procurement and initiation of cell line effort granting Caladrius permission to cryopreserve the tumor and/or to initiate an autologous tumor cell line from excess tissue that has been removed during a medical procedure (e.g., surgically excised).
5. Initiation of Autologous Tumor Cell Line. Caladrius must have received a viable melanoma tumor tissue specimen that has been obtained and processed according to company SOPs to ensure tissue viability. The cell line can be initiated with either a specimen of fresh tumor or tumor that has been previously cryopreserved.
Treatment Phase
1. Successful establishment of an autologous melanoma cell line by Caladrius.
2. Patients with multiple depots of distant metastatic disease must have previously received at least one or more of the following standard treatments: interleukin 2 (IL-2), or ipilimumab, or vemurafenib (if tumor expresses the V600E mutation), or dacarbazine or temozolomide, if not mutated for the V600E mutation, and not felt to be medically appropriate for IL-2 or ipilimumab. These may have been given alone, or in combination with other agents.
3. Medical fitness to undergo a leukapheresis, including peripheral venous access or access by central vein if necessary.
4. Medical fitness for participation in a phase III clinical trial.
* a. ECOG performance status of 0 or 1.
* b. Adequate bone marrow function: absolute neutrophil count (ANC) greater than 1000/mm (3), hematocrit greater than 30%, platelet count greater than 100,000/mm (3), no ongoing transfusion requirements.
* c. Adequate hepatic function: total bilirubin less than 2.0 mg/dL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the upper limit of normal (ULN), albumin greater than 3 g/dL.
* d. Adequate kidney function: creatinine less than or equal to 2.0 mg/dL.
* e. Negative pregnancy test for woman of childbearing potential and use of effective contraception (hormonal or barrier method of birth control) during therapy (women of childbearing potential and men).
5. Extent of disease established within 4 weeks of randomization.
* a. History and Physical Exam by a licensed practitioner.
* b. Fludeoxyglucose(FDG)-based PET/CT or PET scan and CT scan.
* c. Brain MRI demonstrating no new untreated or uncontrolled metastases.
6. Recovery from previous therapies.
* a. At least four weeks (28 days) must have elapsed since any prior systemic therapy at the time of the first dose (six weeks for anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4), and any toxicities experienced must have recovered to a grade 1 or less (except for alopecia or vitiligo).
* b. More than three weeks (at least 22 days) since radiation therapy at the time of the first dose (7 days for single-dose stereotactic radiotherapy such as gamma knife) and recovery from acute toxicities. Patients treated with whole brain radiation must wait at least 22 days after completion of radiation and have radiographic confirmation of lack of progression before proceeding to randomization.
Exclusion Criteria
1. Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
2. Lack of a metastatic melanoma lesion that can be resected.
Treatment Phase
1. Known positive for hepatitis B or C or HIV.
2. Pregnant or lactating women.
3. Underlying cardiac disease associated with known myocardial dysfunction, or active treatment with digoxin or other medications being given to treat heart failure, or unstable angina related to atherosclerotic cardiovascular disease.
4. Diagnosis of any other invasive cancer that requires ongoing treatment or for which there is evidence of active disease.
5. Active, unresolved infection and/or receiving concurrent treatment with parenteral antibiotics (patients are eligible after antibiotics have been discontinued for at least 7 days prior to first dose and evidence of infection has resolved).
6. Other active medical condition that could be imminently life threatening, in the opinion of the investigator, including no active blood clotting or bleeding diathesis.
7. New or uncontrolled brain metastases or leptomeningeal disease and/or taking pharmacological doses of corticosteroids. Brain metastases treated by gamma knife or stereotactic radiotherapy are considered controlled, unless patient requires pharmacologic doses of corticosteroids. It is recognized that tumor necrosis may be confused with tumor progression in interpretation of Brain MRI.
8. Known autoimmune disease, immunodeficiency, or disease process that involves the use of immunosuppressive therapy.
9. Taking other anticancer therapy.
10. Received another investigational drug within 28 days of the first dose.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lisata Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert O Dillman, MD
Role: STUDY_CHAIR
Caladrius Biosciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Irvine, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Orange, California, United States
Santa Monica, California, United States
Aurora, Colorado, United States
Goshen, Indiana, United States
Louisville, Kentucky, United States
Marrero, Louisiana, United States
Baltimore, Maryland, United States
Hackensack, New Jersey, United States
Cincinnati, Ohio, United States
Easton, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Knoxville, Tennessee, United States
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Javed A, Sato S, Sato T. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncol. 2016 Mar;12(6):751-62. doi: 10.2217/fon.16.13. Epub 2016 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-001984-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CL-CA-P01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.